Browse News
Filter News
Found 500,980 articles
-
It’s an often-cited statistic in the job recruitment world: hiring managers typically spend an average of six seconds scanning each resume before deciding whether to discard it or move it along for further review. Six seconds!
-
Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan...
-
It’s no secret that China has become an ever-increasing important component for drug development. Not only is the country seen as a lucrative market for drugs, entities within the country are making heavy investments in the global biotech industry.
-
Shares of Ionis Pharmaceuticals are up more than 10 percent in premarket trading after Biogen handed over $1 billion to support a new 10-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
-
With growing concerns about the rise of drug resistant bacteria, multiple companies are developing new forms of antimicrobials to take on serious health concerns.
-
Plenty of exciting news in the research world. Here’s a look at some of the top stories.
-
The U.S. Food and Drug Administration (FDA)’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously recommended the approval of London, UK-based GW Pharmaceuticals’ Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
-
Novartis Provides Additional Phase III Data for MS Drug Siponimod: Prepares to Seek FDA Approval
4/20/2018
Novartis released new information that showed siponimod consistently reduced the risk of confirmed disability progression in secondary progressive multiple sclerosis (SPMS) patients. -
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
-
Check out these five things you can do to before asking for a promotion.
-
ESSA Pharma Inc. Announces Share Consolidation
4/20/2018
ESSA Pharma Inc., a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that on April 18, 2018 the board of directors of the Company passed a resolution to proceed with the previously announced consolidation of the issued and outstanding common shares of the Company on a basis of one (1) post-Consolidation Common Share for every twenty (20) pre-Consolidation Common Shares
-
QIAGEN Announces FDA Approval of PartoSureTM
4/20/2018
Novel point-of-care test to assess risk of spontaneous preterm birth, reducing unnecessary hospital admissions and safeguarding babies
-
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
4/20/2018
Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases
-
Sodexo Canada and Xposure PR Earn International Communications Award
4/20/2018
Sodexo Canada and its public relations agency, Xposure PR, have been honored with a 2018 Gold Quill Award of Merit in Media Relations from the International Association of Business Communicators (IABC).
-
Prime Therapeutics Finds Costs Double When Switching to New Extended Half-Life Hemophilia Factor Products
4/20/2018
Real-world data analysis shows extended half-life coagulation factor products bring high cost
-
Senomyx Sets First Quarter 2018 Earnings Release Date for Thursday, April 26, 2018 at 4:05 p.m. ET
4/20/2018
Senomyx, Inc. (NASDAQ: SNMX), a leading company using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients and natural high intensity sweeteners, will issue its financial results on Thursday, April 26, 2018 at 4:05 p.m. Eastern time (1:05 p.m. Pacific time) for the first quarter ended March 31, 2018.
-
Vaxart Announces $5 Million Inavir® Revenue Milestone
4/20/2018
2017 Net Sales of Inavir® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment
-
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
4/20/2018
Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company's supplemental New Drug Application (sNDA) which seeks a new indication for ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants
-
Varian Calypso Anchored Beacon Transponder for Lung Receives FDA 510k Clearance
4/20/2018
Varian (NYSE: VAR) today announced it has received FDA 510(k) clearance for its Calypso® Anchored Beacon® transponder.
-
Abaxis To Report Fourth Quarter And Fiscal Year 2018 Financial Results On Thursday, April 26, 2018
4/20/2018
Abaxis, Inc. (Nasdaq: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, has scheduled a conference call to discuss its financial results for the fourth quarter and fiscal year 2018, ended March 31, 2018